Legend Biotech reports Q2 EPS (57c), consensus (60c)

Reports Q2 revenue $73.3M, consensus $54.62M. As of June 30, 2023, after giving effect to the registered direct offering, private placements or warrant exercise noted above, Legend Biotech had approximately $1.5 billion of cash and cash equivalents, time deposits, and short-term investments. “We remain committed to exploring the full potential of CARVYKTI(R) and are pleased with the continued growth of our development program, including two regulatory submissions made during the second quarter,” said Ying Huang, CEO. “Following our most recent fundraising, we are well positioned to advance our pipeline and portfolio. We remain grateful to the investors who support our endeavors.”